Fundraising Fox
/Companies
Sign in

Bionano Genomics

NASDAQ: BNGO

San Diego, US · Delaware corporation · 2 known investors

Find your way into Bionano Genomics

Each arrow is one introduction. Sign up to fill in the first one.

260 people can intro you to Mark

Ask Chris Barbazette to introduce you to Mark Oldakowski

You →Chris · together at Affymetrix, Inc. →Mark

Sign up to find every way you can get introduced to Bionano Genomics

  • Your email: who you already know at Bionano Genomics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Bionano Genomics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome. Its tools serve clinical care, research, and therapeutics applications including hematological malignancies, solid tumors, reproductive health, rare disease, and cell line quality control.

BiotechHealthtechMedical Devices

Founders & leadership

HC
Han CaoFounder
GK
Gulsen KamaExecutive
MOMark Oldakowski
Mark OldakowskiExecutiveHe has extensive experience developing and manufacturing life science and medical device systems and software, managing global R&D teams and large multinational organizations, with expertise in FDA quality systems, design controls, and regulatory compliance.
JDJonathan Dixon
Jonathan DixonExecutive
RER. Erik Holmlin
R. Erik HolmlinExecutive
AC
Alka ChaubeyExecutive
ERErik R. Holmlin
Erik R. HolmlinExecutive
JJ
Joel JungExecutive
LR
Lynne RollinsExecutive

Board

DC
Darren CaiBoard director
BHBrian Halak
Brian HalakBoard directorManaging Partner at Medical Excellence Capital
YL
Yvonne LinneyBoard director

Investors · 2

Hudson BayreportedStamford

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$192.8M disclosed across 8 rounds · 2013–2024

▶$20MraisedJul 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yvonne LinneyDirector
  • Gulsen KamaExecutive Officer
  • David L. BarkerDirector
  • Kristiina VuoriDirector
  • Christopher TwomeyDirector
  • Mark OldakowskiExecutive Officer
  • Jonathan DixonExecutive Officer
  • Hannah MamuszkaDirector
  • R. Erik HolmlinExecutive Officer, Director
  • Albert A. LudererDirector
  • Vincent WongDirector
  • Alka ChaubeyExecutive Officer
  • Aleksandar RajkovicDirector
Offering amount
$20M
Amount sold
$20M
Sales commissions
$400K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedJun 2024 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • R. Erik HolmlinExecutive Officer
Offering amount
$20M
Amount sold
$20M
Minimum investment
$100K
Sales commissions
$1.3M
Placement agents
Canaccord Genuity LLC
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedOct 2023 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Alka Chaubey, Ph.D., FACMGExecutive Officer
  • Vincent Wong, J.D., M.B.A.Director
  • Mark OldakowskiExecutive Officer
  • Albert A. Luderer, Ph.D.Director
  • Gulsen KamaExecutive Officer
  • Kristiina Vuori, M.D., Ph.D.Director
  • Christopher TwomeyDirector
  • Hannah MamuszkaDirector
  • David L. Barker, Ph.D.Director
  • Aleksandar Rajkovic, M.D., Ph.D.Director
  • Yvonne Linney, Ph.D.Director
  • R. Erik Holmlin, Ph.D.Executive Officer, Director
Offering amount
$35M
Amount sold
$35M
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$41.9MraisedOct 2021 · 27 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher TwomeyDirector
  • R. Erik Holmlin, Ph.D.Executive Officer, Director
  • David L. Barker, Ph.D.Director
  • Albert A. Luderer, Ph.D.Director
  • Kristiina Vuori, M.D., Ph.D.Director
  • Soheil ShamsExecutive Officer
  • Hannah MamuszkaDirector
  • Richard ShippyExecutive Officer
  • Alka Chaubey, Ph.D., FACMGExecutive Officer
  • Yvonne Linney, Ph.D.Director
  • Christopher StewartExecutive Officer
  • Jason PriarExecutive Officer
  • Mark OldakowskiExecutive Officer
Offering amount
$41.9M
Amount sold
$41.9M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedMar 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Albert Luderer, Ph.D.Director
  • Junfeng WangDirector
  • Quan ZhouDirector
  • R. Erik Holmlin, Ph.D.Executive Officer, Director
  • Warren RobinsonExecutive Officer
  • Mike WardExecutive Officer
  • Christopher TwomeyDirector
  • David L. Barker, Ph.D.Director
  • Darren Cai, Ph.D.Director
  • Mark BorodkinExecutive Officer
Offering amount
$11.5M
Amount sold
$2.5M
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$68.4MraisedJan 2015 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David BarkerDirector
  • Darren CaiDirector
  • Brian HalakDirector
  • Campbell MurrayDirector
  • Albert LudererDirector
  • Erik R. HolmlinExecutive Officer, Director
  • Tracy WarrenDirector
  • Joel JungExecutive Officer
  • Han CaoExecutive Officer
Offering amount
$68.4M
Amount sold
$68.4M
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJun 2014 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David L. BarkerDirector
  • R. Erik HolmlinExecutive Officer
  • Joel R. JungExecutive Officer
  • Albert A. LudererDirector
  • Han CaoExecutive Officer
  • Tracy WarrenDirector
  • Brian HalakDirector
Offering amount
$6.1M
Amount sold
$5M
First sale
Jun 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15KraisedJan 2014 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • R. Erik HolmlinExecutive Officer, Director
  • David L. BarkerDirector
  • Han CaoExecutive Officer
  • Tracy WarrenDirector
  • Brian HalakDirector
  • Lynne RollinsExecutive Officer
  • Albert A. LudererDirector
Offering amount
$15K
Amount sold
$15K
First sale
Dec 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Acquisitions · 1

Early investors' stakes continue via these deals
Purigen

Purigen Biosystems made an automated benchtop instrument using isotachophoresis to extract and purify nucleic acids from complex biological samples for genomics research.

Frequently asked questions

What does Bionano Genomics do?
Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome. Its tools serve clinical care, research, and therapeutics applications including hematological malignancies, solid tumors, reproductive health, rare disease, and cell line quality control.
Who founded Bionano Genomics?
Bionano Genomics was founded by Han Cao.
Who are Bionano Genomics's investors?
Bionano Genomics's investors include Domain Associates, Hudson Bay.
How much funding has Bionano Genomics raised?
Bionano Genomics has disclosed $192.8M raised across 8 rounds.
Where is Bionano Genomics headquartered?
Bionano Genomics is headquartered in San Diego, US.